Physician profile
Ralph E Russo
NPI 1376510594
$10,754.26
in general payments reported to CMS, 2019-2025
33 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what 79% of Nuclear Cardiology providers received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,992 · 2020: $647 · 2021: $1,541 · 2022: $696 · 2023: $3,184 · 2024: $1,417 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,478 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,477.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $1,442.10 | 2023-2024 | |
| Impulse Dynamics (USA) INC. | $1,372.04 | 2021-2025 | Optimizer, Optimizer |
| Boston Scientific Corporation | $1,178.72 | 2019-2025 | Watchman Flx, Watchman Access System, Watchman |
| Amgen INC. | $1,171.99 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $909.15 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $898.63 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $634.46 | 2019-2025 | Farxiga, Wainua |
| Pfizer INC. | $634.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $391.19 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.31 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $300.95 | 2021-2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $161.83 | 2020-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $144.43 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $137.16 | 2020-2025 | Lifevest |
| Philips North America LLC | $131.91 | 2020-2024 | (5044) Mcot |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $130.62 | 2019-2020 | |
| Edwards Lifesciences Corporation | $91.04 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Alnylam Pharmaceuticals INC. | $89.50 | 2024-2025 | Onpattro, Amvuttra |
| Amarin Pharma, INC. | $80.67 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $75.04 | 2023-2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $54.22 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $44.89 | 2019-2024 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $39.84 | 2023-2024 | Inpefa |
| Ge Healthcare | $36.32 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.00 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $32.58 | 2023 | Arcalyst |
| Agepha Pharma Fz LLC | $31.94 | 2024-2025 | Lodoco |
| Abiomed | $28.14 | 2024 | Impella |
| Avinger INC. | $23.72 | 2022 | |
| Gilead Sciences, INC. | $23.18 | 2019 | |
| Ionis Pharmaceuticals, INC. | $17.19 | 2025 | Tryngolza |
| Actelion Pharmaceuticals US, INC. | $16.38 | 2024 | Opsumit, Uptravi |
| W. L. Gore & Associates, INC. | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.